Showing 4581-4590 of 7587 results for "".
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- Congrats: Dr. Barbara Gilchrest Receives the 24th David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-barbara-gilchrest-receives-the-24th-david-martin-carter-mentor-award/2458556/Barbara A. Gilchrest, MD of Harvard Medical School and Massachusetts General Hospital in Boston received the David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz. Dr. Gilchrest plus the recipients of The Researc
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human
- AAD Survey: Many Use Sunscreen Incorrectlyhttps://practicaldermatology.com/news/aad-survey-many-use-sunscreen-incorrectly/2458561/Many people don’t understand SPF numbers on product labels, and some may not be using sunscreen properly, which could increase their skin cancer risk, the American Academy of Dermatology reports. In a 2016 survey, only 32 percent of respondents knew that an SPF 30 sunscreen do
- Dr. Brandt's Legacy Lives on with New Dr. Brandt® Skincare Advisory Boardhttps://practicaldermatology.com/news/dr-brandts-legacy-lives-on-with-new-dr-brandt-skincare-advisory-board/2458563/Dr. Brandt® Skincare is rolling out a new Advisory Board to elevate the brand and honor Dr. Brandt’s legacy of innovation in dermatology. Frederick Brandt died on April 5, 2015 in his home in Coconut Grove, Florida. The first
- Untreated Sleep Apnea Linked to Melanoma Aggressionhttps://practicaldermatology.com/news/untreated-sleep-apnea-linked-to-melanoma-aggressiveness/2458564/Untreated severe obstructive sleep apnea (OSA) is linked to increased aggressiveness of malignant cutaneous melanoma, according to research presented at the American Thoracic Society 2016 International Conference in San Francisco. The study involved 412 patients, average age 55.8, w
- Feet Get Skin Cancer Too, ACFAS Warnshttps://practicaldermatology.com/news/feet-get-skin-cancer-too-acfas-warns/2458565/Skin cancer of the foot is prevalent and can be fatal if not caught early, the American College of Foot and Ankle Surgeons (ACFAS) warns. While all types of skin cancer, including squamous cell and basal cell carcinoma, can be found
- Alphaeon Launches PROVOQUE™ Facial Serumhttps://practicaldermatology.com/news/alphaeon-launches-provoque-facial-serum/2458567/Alphaeon Corporation has launched PROVOQUE™ Facial Serum to help address the visible signs of skin aging. PROVOQUE Facial Serum is a stem cell-conditioned media containing growth factors secreted by stem cells.
- FDA Approves New Combo Drug Plus Device Treatment for AKshttps://practicaldermatology.com/news/fda-approves-new-combo-drug-plus-device-treatment-for-aks/2458568/The FDA approved Biofrontera AG’s combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED for photodynamic therapy (PDT) treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp. The approval covers lesion-directed as well as field-directed